# Immune regulation and lymphangiogenesis by lymphatic endothelial cells in the decidua in severe preeclampsia

**Authors:** Suhra Kim, Yeji Lee, Ja-Young Kwon, Yong-Sun Maeng

PMC · DOI: 10.1038/s41598-026-35667-3 · Scientific Reports · 2026-01-13

## TL;DR

This study explores how lymphatic vessels in the womb lining may contribute to immune imbalances in severe preeclampsia, a serious pregnancy complication.

## Contribution

The study identifies molecular and functional impairments in decidual lymphatic endothelial cells in severe preeclampsia.

## Key findings

- Decidual lymphatic endothelial cells from severe preeclampsia show reduced migration, adhesion, and sprouting.
- Impaired Akt-eNOS-nitric oxide signaling in these cells may suppress cytotoxic T-cell activation.
- Altered gene expression in preeclampsia is linked to lymphatic development and immune regulation.

## Abstract

Lymphatic vasculature regulates lymphocyte trafficking and modulates adaptive immunity. Imbalanced immune cells at the maternal-fetal interface may contribute to severe preeclampsia (PE). Impaired placental lymphangiogenesis and immune dysregulation could contribute to PE but supporting evidence is limited. Here, we investigate the association between lymphangiogenesis and immune regulation in severe PE. First, we identified the presence of LYVE1-positive lymphatic vessels in the decidua, and then decidual lymphatic endothelial cells (dLECs) were isolated and cultured from chorioamniotic membranes obtained at cesarean section from women with PE (n = 15) and gestational age-matched controls (n = 15). The cells were identified by LYVE1, Prox1, and CD31 expression. Gene expression analysis showed the significant different gene expression profiles in PE compared to normal (lymphatic vessel development, immune cell trafficking and T-cell activation regulation). dLECs from PE pregnancies showed substantially reduced migration, adhesion, morphological differentiation, and decreased lymphatic sprouting in a 3D lymphatic ring assay compared with normal. Additionally, they exhibited low chemokine ligand 21 expression, impaired dendritic cell recruitment, and reduced Akt-eNOS-nitric oxide signaling, which suppresses decidual cytotoxic T-cell activation in decidua. Collectively, our findings suggest that impaired lymphatic vessel function and molecular alterations in the decidua may disrupt immune regulation and contribute to severe PE.

The online version contains supplementary material available at 10.1038/s41598-026-35667-3.

## Linked entities

- **Genes:** LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 10894], PROX1 (prospero homeobox 1) [NCBI Gene 5629], PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], NOS3 (nitric oxide synthase 3) [NCBI Gene 4846]
- **Diseases:** preeclampsia (MONDO:0005081)

## Full-text entities

- **Genes:** PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, AMELX (amelogenin X-linked) [NCBI Gene 265] {aka AI1E, AIH1, ALGN, AMG, AMGL, AMGX}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 10894] {aka CRSBP-1, HAR, LYVE-1, XLKD1}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, NR2F2 (nuclear receptor subfamily 2 group F member 2) [NCBI Gene 7026] {aka ARP-1, ARP1, CHTD4, COUPTF2, COUPTFB, COUPTFII}, PROX1 (prospero homeobox 1) [NCBI Gene 5629], SEMA3A (semaphorin 3A) [NCBI Gene 10371] {aka COLL1, HH16, Hsema-I, Hsema-III, SEMA1, SEMAD}, Prox1 (prospero homeobox 1) [NCBI Gene 19130] {aka A230003G05Rik, PROX-1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Flt4 (FMS-like tyrosine kinase 4) [NCBI Gene 14257] {aka Chy, Flt-4, VEGFR-3, VEGFR3}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], Lyve1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 114332] {aka 1200012G08Rik, Crsbp-1, Lyve-1, Xlkd1}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Ccr7 (C-C motif chemokine receptor 7) [NCBI Gene 12775] {aka CC-CKR-7, CCR-7, CD197, Cdw197, Cmkbr7, EBI1}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, F2 (coagulation factor II) [NCBI Gene 14061] {aka Cf-2, Cf2, FII}, SRY (sex determining region Y) [NCBI Gene 6736] {aka SRXX1, SRXY1, TDF, TDY}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, SOX18 (SRY-box transcription factor 18) [NCBI Gene 54345] {aka HLTRS, HLTS}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, AMELY (amelogenin Y-linked) [NCBI Gene 266] {aka AMGL, AMGY}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, CCL21 (C-C motif chemokine ligand 21) [NCBI Gene 6366] {aka 6Ckine, CKb9, ECL, SCYA21, SLC, TCA4}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, CCL16 (C-C motif chemokine ligand 16) [NCBI Gene 6360] {aka CKb12, HCC-4, ILINCK, LCC-1, LEC, LMC}, Hnrnpk (heterogeneous nuclear ribonucleoprotein K) [NCBI Gene 15387] {aka Hnrpk, KBBP, NOVA}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, PLXNA1 (plexin A1) [NCBI Gene 5361] {aka DWOPNED, NOV, NOVP, PLEXIN-A1, PLXN1}, CD14 (CD14 molecule) [NCBI Gene 929], CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}
- **Diseases:** miscarriage (MESH:D000022), pulmonary/respiratory diseases (MESH:D012140), chronic (MESH:D002908), insulin resistance (MESH:D007333), metastasis (MESH:D009362), breast cancer (MESH:D001943), inflammation (MESH:D007249), N (MESH:C536108), arthritis (MESH:D001168), endothelial (MESH:D005642), PE (MESH:D011225), lymphatic malformations (MESH:D008209), pregnancy failure (MESH:D051437), neurodegenerative diseases (MESH:D019636), preeclamptic (MESH:C538543), hypertension (MESH:D006973), obesity (MESH:D009765), autoimmune disease (MESH:D001327), fetal growth restriction (MESH:D005317), chorioamnionitis (MESH:D002821), rheumatoid arthritis (MESH:D001172), proteinuria (MESH:D011507), cancer (MESH:D009369)
- **Chemicals:** H&amp;E (MESH:D006371), polyvinylidene fluoride (MESH:C024865), FITC (MESH:D016650), Nitrite (MESH:D009573), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MESH:C022616), eosin (MESH:D004801), EDTA (MESH:D004492), DMSO (MESH:D004121), paraformaldehyde (MESH:C003043), sulfanilamide (MESH:D000077145), agmatine (MESH:D000376), Hematoxylin (MESH:D006416), 4, 4'-diamino-diphenylsulfone (MESH:D003622), PBS (MESH:D007854), ethidium bromide (MESH:D004996), MTT (MESH:C070243), hyaluronan (MESH:D006820), agarose (MESH:D012685), HCl (MESH:D006851), N (MESH:D009584), phenol red (MESH:D010637), superoxide anion (MESH:D013481), calcium (MESH:D002118), TRIzol (MESH:C411644), N-(1-naphthyl) ethylenediamine (MESH:C008588), rauwolscine (MESH:D015016), Nitrate (MESH:D009566), DAF-FM (-), 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (MESH:C503301), Cytodex 3 (MESH:C052839), NO (MESH:D009569)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** WI-38 — Homo sapiens (Human), Finite cell line (CVCL_0579)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12881592/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12881592/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12881592/full.md

---
Source: https://tomesphere.com/paper/PMC12881592